• 作者： 何橈通; 江慧鈴; 蔡蘅; 周澤義; 郭清輝
• 作者服務機構： 榮民總醫院‧內科部‧新陳代謝科; 國防醫學院‧內科學系
• 中文摘要： 為評估「貝脂利」之降血脂作用，本研究選取原發性高血脂症，及糖尿病合併高血脂症患者，各12例，加以觀察。每
  位病人均服用安慰劑及「貝脂利」各三個月，其先後次序，由隨機抽樣決定。藥量為一天口服三次，每次一錠二百毫克。
  以血中「空腹血漿糖」及「糖化血素」做為糖尿病控制狀態之指標，並測定血中總?固醇，高密度血脂蛋白?固醇，及三酸
  甘油酯等，以觀察此藥之降血脂效果。
  無母數統計方法用以計算其差異之顯著與否。結果顯示，在原發性及在糖尿病合併有血脂過高症之兩組病人中，「
  貝脂利」均促使血中三酸甘油酯值下降，及高密度血脂蛋白?固醇值上升。血中總?固醇濃度雖未呈有意義之下降，但
  其「總?固醇／高密度血脂蛋白?固醇」比值，均呈有意義的下降。因血中「空腹血漿糖」及「糖化血色素」值，在治療期間與
  服用安慰劑期間，並無差異，所以此種血脂下降效果，不能用糖犀病之控制改善來解釋，而需歸功於「貝脂利」本身的降
  血脂作用。除二位病人在短期服用「貝脂利」期間，有輕微及短暫的臉部潮紅現象外，無其他副作用。名
• 英文摘要： Bezalip (bezafibrate), at an oral dosage of 200 mg three times a day, has been used on 12 patientswith idiopathic hyperlipidemia, and on 12 patients with hyperlipidemia superimposed with diabetes mel-litus. Each patient received bezafibrate for 3 months and placebo for 3 months. Blood glycosylatedhemoglobin and fasting plasma glucose (FPG) were used as indices of diabetic control. Serumtriglyceride (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), and TC/HDL-Cratio were measured and calculated in order to compare the antilipernic effects of bezafibrate with that ofplacebo. Non-parametric Wilcoxon test was used for statistical analysis. In both the idiopathic group anddiabetic group, bezafibrate significantly lowered the serum levels of TG and TC/HDL-C, as well as elevatedthe level of HDL-C. The serum TC levels were not significantly altered in either of the groups. Theseeffects could not be ascribed to an improved diabetic control, since the percent changes of were notdifferent between the bezafibrate periods and the placebo periods. There were no significant facial flush-ing, nor other side effects during the treatment with bezafibrate. It is concluded that bezafibrate hasantilipemic effects, and may be helpful in reducing the atherogenic risks.
• 中文關鍵字： hyperlipidemia; diabetes mellitus; atherosclerosis; bezafibrate; clinical trial
• 英文關鍵字： --